论文部分内容阅读
一项Ⅲ期试验的研究结果显示,每周一次阿必鲁泰比每天一次利拉鲁肽耐受性更好,且效果相似,不过,阿必鲁泰未能达到预设的非劣性标准。在为期32周的试验中,纳入了二甲双胍、噻唑烷二酮类、磺脲类或其任意组合血糖控制不佳(糖化血红蛋白为7%～10%)的2型糖尿病患者,被随机分为两组:阿必鲁泰组(404名)和利拉鲁肽组(408名。在研究过程中,阿必鲁泰组的患者起始剂量为30mg,直至增加至50mg;利拉鲁肽组患者起始剂量为0.6mg/d,第2周为1.2mg,第3周增加至1.8mg。该研究中,患者平均年龄为55.6±10.1岁,
Results from a phase III study showed that once weekly, albiotripe is more tolerated and has similar effects than liraglutide once daily, however, Albus Luther has not met the preset non-inferiority criteria. In a 32-week trial, patients with type 2 diabetes who did not receive controlled metformin, thiazolidinediones, sulfonylureas, or any combination thereof (glycosylated hemoglobin, 7% to 10%) were randomized to two Group: Alpiride Group (404) and Liraglutide Group (408). During the study, the starting dose of alpiride group was 30 mg until it increased to 50 mg; in the liraglutide group The initial dose was 0.6 mg / day, 1.2 mg in week 2 and 1.8 mg in week 3. In this study, the mean age of patients was 55.6 ± 10.1 years,